Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: a retrospective bicenter study by the SFRO Brachytherapy Group.
Fiche publication
Date publication
janvier 2023
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MARTIN Etienne, Pr PEIFFERT Didier, Dr QUIVRIN Magali
Tous les auteurs :
Ka K, Schiappa R, Terlizzi M, Mallet F, Martin E, Chand ME, Demogeot N, Peiffert D, Pommier P, Quivrin M, Kissel M, Pasquier C, Khalifa J, Hannoun-Levi JM, Blanchard P
Lien Pubmed
Résumé
Radiotherapy dose escalation improves biochemical control in intermediate- or high-risk prostate cancer. Brachytherapy boost was shown to further improve biochemical control compared to radiotherapy alone in three randomized trials. The SFRO brachytherapy group sought to evaluate the efficacy and toxicity of BT-boost for intermediate and high-risk prostate cancer in real life, and to determine prognostic factors for efficacy and toxicity.
Mots clés
brachytherapy, prostate cancer, radiotherapy
Référence
Radiother Oncol. 2023 01 10;:109460